In the first half of 2025, Abbott Laboratories showed steady growth in the US medical device sector, with some products experiencing declines in average selling prices. However, top revenue product lines maintained consistent prices, indicating resilience to economic pressures and tariff policies.

Analysis of Abbott’s highest-volume products revealed varying trends in ASP changes between 2024 and 2025, possibly reflecting shifting purchasing strategies in US healthcare facilities due to evolving public health priorities and cost considerations.

Abbott reported a strong first half in 2025, with US medical device sales increasing by 14.8% compared to the previous year. Key product lines like MitraClip, Ensite X, and Tactiflex continued to perform well, contributing to Abbott’s 18% market share in the US cardiovascular market, according to GlobalData.

Despite overall growth, Abbott’s US diagnostics experienced a slight decline in sales in the second quarter of 2025, particularly in point-of-care and rapid diagnostics, possibly due to reduced demand for Covid-19 testing. This shift in demand may have impacted some of Abbott’s high-volume sales.

Read more at KHL Group: Abbott Laboratories shows growth in core products amid market shifts